Phenotypically matched vs. traditional screen method for preparing red blood cell units in patients with abnormal placentation: A decision analysis approach

Vox Sanguinis

Volumn 107, Issue 4, 2014, Pages 399-406

  Pham, H P ^a,b   Kim, C H ^c   Schwartz, J ^b  

^a University of Alabama at Birmingham   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^c Mailman School of Public Health   (United States)

Author keywords

Cost effectiveness; Phenotypically matched; Placenta accreta; Placenta previa; Transfusion requirement

Indexed keywords

ADULT; COST BENEFIT ANALYSIS; ECONOMICS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; PERINATAL PERIOD; PHENOTYPE; PREGNANCY; PROBABILITY; REPRODUCTION;

ADULT; COST-BENEFIT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMORRHAGE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MARKOV CHAINS; PERIPARTUM PERIOD; PHENOTYPE; PLACENTATION; PREGNANCY;

EID: 84911890384     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12176     Document Type: Article

References (22)

1. Oyelese Y, Smulian JC: Placenta previa, placenta accreta, and vasa previa. Obstet Gynecol 2006; 107:927-941
2. Silver RM, Landon MB, Rouse DJ, et al.: Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006; 107:1226-1232
3. Wu S, Kocherginsky M, Hibbard JU: Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol 2005; 192:1458-1461
4. Miller DA, Chollet JA, Goodwin TM: Clinical risk factors for placenta previa-placenta accreta. Am J Obstet Gynecol 1997; 177:210-214
5. Faiz AS, Ananth CV: Etiology and risk factors for placenta previa: an overview and meta-analysis of observational studies. J Matern Fetal Neonatal Med 2003; 13:175-190
6. Abuhamad A: Morbidly adherent placenta. Semin Perinatol 2013; 37:359-364
7. Rao KP, Belogolovkin V, Yankowitz J, et al.: Abnormal placentation: evidence-based diagnosis and management of placenta previa, placenta accreta, and vasa previa. Obstet Gynecol Surv 2012; 67:503-519
8. Eller AG, Bennett MA, Sharshiner M, et al.: Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol 2011; 117:331-337
9. Doumouchtsis SK, Arulkumaran S: The morbidly adherent placenta: an overview of management options. Acta Obstet Gynecol Scand 2010; 89:1126-1133
10. Robinson BK, Grobman WA: Effectiveness of timing strategies for delivery of individuals with placenta previa and accreta. Obstet Gynecol 2010; 116:835-842
11. O'Brien JM, Barton JR, Donaldson ES: The management of placenta percreta: conservative and operative strategies. Am J Obstet Gynecol 1996; 175:1632-1638
12. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-338
13. Heddle NM, Klama L, Frassetto R, et al.: A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy. Transfusion 1993; 33:217-220
14. Kacker S, Ness PM, Savage WJ, et al.: Cost-effectiveness of prospective red blood cell antigen matching to prevent alloimmunization among sickle cell patients. Transfusion 2014; 54:86-97
15. Lee BK, Ploner A, Zhang Z, et al.: Constructing a population-based research database from routine maternal screening records: a resource for studying alloimmunization in pregnant women. PLoS One 2011; 6:e27619
16. Gottvall T, Filbey D: Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 2008; 87:843-848
17. Nordvall M, Dziegiel M, Hegaard HK, et al.: Red blood cell antibodies in pregnancy and their clinical consequences: synergistic effects of multiple specificities. Transfusion 2009; 49:2070-2075
18. Gunduz E, Meltem Akay O, Teke HU, et al.: Incidence of red-cell alloimmunization due to non-anti-D antibodies during pregnancy: an experience from Turkey. Transfus Apher Sci 2010; 43:261-263
19. Moise KJ Jr: Non-anti-D antibodies in red-cell alloimmunization. Eur J Obstet Gynecol Reprod Biol 2000; 92:75-81
20. AABB: CMS Publishes 2013 Hospital Outpatient Prospective Payment System Rule AABB, 2013. Available at: http://www.aabb.org/programs/reimbursementinitiatives/Pages/13hoppsrule.aspx (Last accessed 2 February 2014).
21. Le N, Harach ME, Kay JK, et al.: Establishing an antigen-negative red blood cell inventory in a hospital-based blood bank. Transfusion 2014; 54:285-288
22. Shirey RS, Boyd JS, Parwani AV, et al.: Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002; 42:1435-1441